CL2016001742A1 - Anticuerpos anti-baff novedosos - Google Patents
Anticuerpos anti-baff novedososInfo
- Publication number
- CL2016001742A1 CL2016001742A1 CL2016001742A CL2016001742A CL2016001742A1 CL 2016001742 A1 CL2016001742 A1 CL 2016001742A1 CL 2016001742 A CL2016001742 A CL 2016001742A CL 2016001742 A CL2016001742 A CL 2016001742A CL 2016001742 A1 CL2016001742 A1 CL 2016001742A1
- Authority
- CL
- Chile
- Prior art keywords
- novel anti
- baff antibodies
- baff
- antibodies
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461934124P | 2014-01-31 | 2014-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016001742A1 true CL2016001742A1 (es) | 2017-07-28 |
Family
ID=53754266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001742A CL2016001742A1 (es) | 2014-01-31 | 2016-07-07 | Anticuerpos anti-baff novedosos |
Country Status (14)
Country | Link |
---|---|
US (3) | US9840543B2 (es) |
EP (1) | EP3099715B1 (es) |
JP (1) | JP6511459B2 (es) |
KR (1) | KR20160113715A (es) |
CN (1) | CN105873949A (es) |
AU (1) | AU2015315834B2 (es) |
BR (1) | BR112016014731A2 (es) |
CA (1) | CA2934965A1 (es) |
CL (1) | CL2016001742A1 (es) |
EA (1) | EA033604B1 (es) |
IL (2) | IL246113B (es) |
MX (1) | MX367661B (es) |
PH (1) | PH12016501366A1 (es) |
WO (1) | WO2016039801A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JP6511459B2 (ja) | 2014-01-31 | 2019-05-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規な抗baff抗体 |
US10280231B2 (en) * | 2015-07-23 | 2019-05-07 | Boehringer Ingelheim International Gmbh | Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof |
WO2017223534A2 (en) * | 2016-06-24 | 2017-12-28 | Anthera Pharmaceuticals, Inc. | Methods of treating iga nephropathy and henoch-schönlein purpura nephritis using a b-cell activating factor (baff) inhibitor |
CN109311988A (zh) * | 2016-07-06 | 2019-02-05 | 上海开拓者生物医药有限公司 | 一种BlyS抗体及其制备方法和应用 |
US10869522B2 (en) | 2016-11-04 | 2020-12-22 | Totes Isotoner Corporation | Footwear, and methods of preparing same |
US20200385478A1 (en) * | 2018-01-05 | 2020-12-10 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
WO2019195770A1 (en) | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
CN114746120A (zh) * | 2019-10-03 | 2022-07-12 | Atyr 医药公司 | 包含抗nrp2抗体的组合物和方法 |
KR20220155336A (ko) * | 2020-03-18 | 2022-11-22 | 킨드레드 바이오사이언시스, 인코포레이티드 | 수의학적 용도를 위한 항-il4 수용체 항체 |
CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
IL302412A (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies |
CN112516303A (zh) * | 2020-11-18 | 2021-03-19 | 华中科技大学同济医学院附属协和医院 | Baff抗体在制备脓毒血症药物中的应用 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE69315847T2 (de) | 1992-08-21 | 1998-06-25 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6812327B1 (en) * | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
CN100340292C (zh) | 1999-01-25 | 2007-10-03 | 比奥根艾迪克Ma公司 | Baff,其封闭剂以及它们在b细胞应答的调节中的应用 |
AU6842701A (en) * | 2000-06-16 | 2002-01-14 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
US20080050381A1 (en) | 2004-08-31 | 2008-02-28 | Tsutomu Takeuchi | Antihuman Baff Antibody |
WO2006031718A2 (en) | 2004-09-15 | 2006-03-23 | The Uab Research Foundation | Compositions and methods for modulating rank activities |
ATE535611T1 (de) | 2004-09-15 | 2011-12-15 | Kowa Co | Verfahren zum screening des baff-suppressors oder inhibitors |
US20090215071A1 (en) * | 2005-07-28 | 2009-08-27 | Teresa Cachero | Methods of targeting baff |
US8617545B2 (en) | 2005-10-13 | 2013-12-31 | Biogen Idec Ma Inc. | Methods for use with BAFF antagonists |
TW200833711A (en) | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
KR101545795B1 (ko) | 2008-07-17 | 2015-08-19 | 노파르티스 아게 | 치료학적 항체에 대한 조성물 및 사용 방법 |
WO2010126898A1 (en) * | 2009-04-27 | 2010-11-04 | The Trustees Of The University Of Pennsylvania | Methods for reducing the level of alloantibodies in a subject |
WO2011031835A1 (en) | 2009-09-09 | 2011-03-17 | The Uab Research Foundation | Chimeric dr5 polypeptides and uses thereof |
WO2011053783A2 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Ax213 and ax132 pcsk9 antagonists and variants |
KR101647871B1 (ko) | 2010-03-05 | 2016-08-11 | 에프. 호프만-라 로슈 아게 | 인간 csf-1r에 대한 항체 및 이의 용도 |
EP2818478B1 (en) | 2011-10-28 | 2017-02-01 | Regeneron Pharmaceuticals, Inc. | Humanized IL-6 and IL-6 receptor |
AR090626A1 (es) | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JP6511459B2 (ja) * | 2014-01-31 | 2019-05-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規な抗baff抗体 |
-
2015
- 2015-01-30 JP JP2016549322A patent/JP6511459B2/ja active Active
- 2015-01-30 KR KR1020167023947A patent/KR20160113715A/ko not_active Application Discontinuation
- 2015-01-30 EA EA201691541A patent/EA033604B1/ru not_active IP Right Cessation
- 2015-01-30 EP EP15703426.5A patent/EP3099715B1/en active Active
- 2015-01-30 US US14/609,756 patent/US9840543B2/en active Active
- 2015-01-30 CN CN201580003487.1A patent/CN105873949A/zh active Pending
- 2015-01-30 BR BR112016014731A patent/BR112016014731A2/pt not_active Application Discontinuation
- 2015-01-30 AU AU2015315834A patent/AU2015315834B2/en not_active Ceased
- 2015-01-30 WO PCT/US2015/013711 patent/WO2016039801A1/en active Application Filing
- 2015-01-30 MX MX2016009877A patent/MX367661B/es active IP Right Grant
- 2015-01-30 CA CA2934965A patent/CA2934965A1/en not_active Abandoned
-
2016
- 2016-06-08 IL IL246113A patent/IL246113B/en not_active IP Right Cessation
- 2016-07-07 CL CL2016001742A patent/CL2016001742A1/es unknown
- 2016-07-11 PH PH12016501366A patent/PH12016501366A1/en unknown
-
2017
- 2017-11-06 US US15/803,993 patent/US10377804B2/en active Active
-
2019
- 2019-05-26 IL IL266864A patent/IL266864A/en unknown
- 2019-06-25 US US16/451,333 patent/US11370818B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2934965A1 (en) | 2016-03-17 |
MX367661B (es) | 2019-08-30 |
EA201691541A1 (ru) | 2016-12-30 |
US11370818B2 (en) | 2022-06-28 |
US20190309034A1 (en) | 2019-10-10 |
US10377804B2 (en) | 2019-08-13 |
US20150218267A1 (en) | 2015-08-06 |
EA033604B1 (ru) | 2019-11-08 |
KR20160113715A (ko) | 2016-09-30 |
IL266864A (en) | 2019-07-31 |
IL246113B (en) | 2019-06-30 |
BR112016014731A2 (pt) | 2017-09-19 |
MX2016009877A (es) | 2016-10-14 |
JP2017505622A (ja) | 2017-02-23 |
AU2015315834A1 (en) | 2016-06-23 |
CN105873949A (zh) | 2016-08-17 |
PH12016501366A1 (en) | 2016-08-15 |
AU2015315834B2 (en) | 2019-12-12 |
IL246113A0 (en) | 2016-07-31 |
EP3099715B1 (en) | 2020-11-18 |
EP3099715A1 (en) | 2016-12-07 |
JP6511459B2 (ja) | 2019-05-15 |
US20180127474A1 (en) | 2018-05-10 |
WO2016039801A1 (en) | 2016-03-17 |
US9840543B2 (en) | 2017-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301117I2 (nl) | trastuzumab deruxtecan | |
KR102355950B9 (ko) | Tigit에 대한 항체 | |
DK3344654T3 (da) | Anti-lag-3-antistoffer | |
DK3332006T3 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
IL266864A (en) | New anti-baff antibodies | |
DK3126395T3 (da) | Multispecifikke antistoffer | |
BR112017001385A2 (pt) | anticorpos anti-pd-1 | |
DK3191517T3 (da) | Krydsreaktive siglec-antistoffer | |
DK3183272T3 (da) | Asymmetriske multispecifikke antistoffer | |
DK3556777T3 (da) | Multispecifikke antistofkonstrukter | |
DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
DK3157559T3 (da) | Anti-axl-antistoffer | |
DK3140653T3 (da) | Direkte immunhistokemianalyse | |
DK3164414T3 (da) | Antistoffer for IL-15 | |
DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
DK3110442T3 (da) | Modificerede meningokok-fhbp-polypeptider | |
DK3215530T3 (da) | Forbedrede il-6 antistoffer | |
CL2016002165A1 (es) | Compuestos de aminocarbonilcarbamato | |
DK3148701T3 (da) | Separator | |
DK3092003T3 (da) | Hidtil ukendt anti-netrin-1-antistof | |
FR3025617B1 (fr) | Architecture bi-voies | |
DK3191466T3 (da) | Azetidinyloxyphenylpyrrolidinforbindelser | |
DK3484921T3 (da) | Anti-IL-22R antistoffer | |
FI20145330A (fi) | Immunomääritys |